Lixisenatide hmoov

Lixisenatide hmoov lag luam wholesale Tuam Tshoj tsum|GLP-1 Receptor Agonist API rau Obesity, Diabetes Research & Factory Direct Bulk Supply

Cov ntsiab lus tseem ceeb

• Ua rau cov piam thaj - nyob ntawm insulin tso tawm kom txo qis kev pheej hmoo ntawm hypoglycemia
• Suppresses postprandial ntshav qabzib surges
• Slows plab hnyuv ntxwm thiab txhim kho satiety rau kev tswj qhov hnyav me
• Inhibits glucagon tso tawm kom stabilizing ntshav qab zib
• Tawm tsam DPP-4 degradation los txhawb kev noj ib zaug ib hnub

Lixisenatide hmoovyog 44-amino-acid synthetic GLP-1 receptor agonist peptide siv hauv kev tshawb nrhiav kab mob metabolic thiab kev txhim kho tshuaj ntshav qab zib hom 2.

Nws muaj C-terminal polylysine hloov kho uas txhim kho kev tiv thaiv rau DPP-4 enzymatic degradation thiab txuas ntxiv hauv vivo stability.

Cov khoom no yog muab los ua cov dawb rau tawm- cov hmoov dawb ua raws li cov qauv GMP nruj, siv Fmoc khoom-theem peptide synthesis (SPPS), ua raws li ntau- kauj ruam HPLC purification thiab desalting.

1. Nws txhawb nqa cov piam thaj li cas -Kev tso tawm cov tshuaj insulin?

Lixisenatide hmoovactivates GLP-1 receptors ntawm pancreatic -cells, txhim kho cov tshuaj insulin tsuas yog nyob rau hauv cov ntshav qabzib siab, yog li txo qis kev pheej hmoo ntawm hypoglycemia.

2. Vim li cas nws thiaj tswj tau cov qib qabzib tom qab?

Nws ua rau lub plab zom mov qeeb, txo cov piam thaj hauv plab zom mov, thiab ua kom muaj txiaj ntsig zoo tom qab cov piam thaj nce ntxiv.

3. Nws cuam tshuam li cas rau kev noj qab haus huv txoj cai?

Nws ua rau lub hauv nruab nrab paj hlwb GLP-1 receptors, ua kom satiety thiab txo cov calorie kom tsawg, txhawb lub cev qhov hnyav hauv kev tshawb fawb metabolic.

4. Puas yog Cardiovascularly Neutral?

Cov ntaub ntawv pov thawj kho mob qhia tias tsis muaj kev nce ntxiv hauv cov xwm txheej tseem ceeb hauv plawv, txhawb kev tshawb fawb ntev - metabolic thiab kev sib xyaw ua ke.

5. Nws tiv thaiv DPP-4 Degradation li cas?

Kev hloov pauv C-terminal polylysine txo qis enzymatic cleavage los ntawm DPP-4, txhim kho peptide stability thiab txuas ntxiv kev ua tshuaj.

6. Vim li cas thiaj haum rau cov tshuaj txhaj tshuaj?

Nws pom zoo aqueous solubility thiab tsis muaj impurity lub nra, making nws tsim nyog rau cov ntawv txhaj tshuaj xws li cov koob txhaj tshuaj prefilled thiab lyophilized hmoov.

• Hom 2 mob ntshav qab zib mellitus tshuaj tsim thiab tsim
• Postprandial glucose tswj kev tshawb fawb
• GLP-1 receptor mechanism kev tshawb fawb
• Obesity thiab metabolic syndrome qauv
• Kev sib xyaw ua ke nrog cov tshuaj insulin lossis tshuaj tiv thaiv qhov ncauj
• Peptide injectable formulation kev loj hlob

1. Nws Yuav Tswj Insulin thiab Glucagon secretion li cas?

Nws qhib GLP-1 receptors ntawm pancreatic -cells thiab -cells, txhawb nqa cov piam thaj-dependent insulin secretion thaum suppressing glucagon tso tawm.

2. Yuav txo qis Postprandial Hyperglycemia li cas?

Nws ua rau lub plab zom mov qeeb, qeeb kev nqus cov zaub mov thiab txo qis tom qab- noj mov qabzib mus ncig ua si.

3. Nws cuam tshuam li cas rau kev noj qab haus huv?

Nws hla cov ntshav-hlwb teeb meem thiab activates hypothalamic GLP-1 receptors, txo qab los noj mov thiab caloric kom tsawg.

4. Nws Ua li cas thiaj ua tau Enzymatic Stability?

Kev hloov kho C-terminal polylysine txo qis kev cuam tshuam rau DPP-4 degradation, txhawb nqa kev ua haujlwm lom neeg.

GMP- tau lees paub qhov chaw tsim khoom hauv chav huv

Tsim nyog raw khoom mus nrhiav thiab chaw muag khoom audit system

Tag nrho batch traceability thoob plaws txhua theem ntau lawm

Kev xaiv thib peb -kev txheeb xyuas qhov tseeb muaj

• GMP- tau lees paub qhov chaw tsim khoom hauv chav huv
• Tsim nyog raw khoom mus nrhiav thiab chaw muag khoom audit system
• Tag nrho batch traceability thoob plaws txhua theem ntau lawm
• Kev tshawb fawb ntev - lub sij hawm thiab nrawm nrawm ntawm -20 degree
• Kev xaiv thib peb -kev txheeb xyuas qhov tseeb muaj

Cim npe nrov: Lixisenatide hmoov, Tuam Tshoj lixisenatide hmoov manufacturers, lwm tus neeg, Hoobkas